You searched for "simulation"

2436 results found

My Top Five: Key insights from recent research into uveitis in adults

Uveitis, characterised by inflammation of the uvea – the eye’s middle layer comprising the iris, ciliary body, and choroid – remains a leading cause of visual impairment worldwide [1]. It primarily affects adults aged 20–50 years. Untreated uveitis may cause...

Novel retinal pigment metric tackles bias in AI models

Researchers have developed an innovative metric for objectively classifying pigmentation in a retinal image, rather than using subjective social constructs like ethnicity or other demographic variables, as is currently the case when building health datasets. Called the Retinal Pigment Score...

Topcon Healthcare Launches IDHea™ to Fuel AI and Digital Health Innovation from the Eye

Topcon Healthcare, Inc., a global leader in robotic diagnostics and digital health solutions, announced the launch of the Institute of Digital Health (IDHea™), an ocular data-as-a-service platform designed to accelerate AI research and digital health innovation. IDHea provides fast and...

Major grant secured to transform immune cell imaging research

A research team has been awarded significant funding by the National Institute for Health and Care Research (NIHR) to develop an innovative drug-device combination that aims to revolutionise how individual immune cells are monitored and treated in patients at Moorfields...

Does bariatric surgery prevent progression of diabetic retinopathy?

The authors report a retrospective observational study of T2DM patients who underwent bariatric surgery between 2009 and 2015. Preoperative and postoperative weight, HbA1c, and annual diabetic retinopathy (DR) screening results were obtained from medical records. Patients with preoperative retinal screening...

Intravitreal afibercept and ranibizumab for PCV

This is a retrospective, interventional series comprising 98 eyes with polypidal choroidal vasculopathy (PCV) with the aim of comparing treatments with afibercept and ranibizumab, highlighting any differences in their efficacy. Case notes and imaging (FFA / ICG / OCT) were...

25-gauge PPV for retained lens fragments

This was a retrospective study including 40 eyes of 40 patients with mean age of 78 years, 19 females and 21 males, who underwent 25-gauge pars plana vitrectomy (PPV) for retained lens fragments with a minimum of six months of...

Comparison of retinal pigment epithelium-choroid graft surgery and anti-VEGF therapy in patients with wet AMD

This was a randomised intervention study in wet AMD patients to investigate benefits of free RPE-choroid graft transplantation surgery versus (continuation of) anti-VEGF treatment. Twenty patients who met the inclusion criteria were subdivided into three subgroups, i.e. RPE tears involving...

Endophthalmitis after intravitreal anti-VEGF injection

The authors report the results of a retrospective multicentre study conducted at 17 retina referral centres to investigate the microbial spectrum of endophthalmitis after anti-VEGF injections. A total of 83 cases of culture-positive endophthalmitis (58.4%) were included. The most frequent...

Suture-less flanged IOL fixation vs. conventional sutured SF in IOL dislocation

The authors report the analysis of a prospective, comparative cohort study on 103 consecutive patients (103 eyes) with intraocular lens (IOL) dislocation who underwent vitrectomy with IOL removal and sutured scleral fixation (SF) (53 eyes) or flanged IOL fixation (50...

Effect of syringe-filling technique and risk for endophthalmitis after intravitreal injection of anti-VEGF agents

In this retrospective study the authors compare the risk for post-injection endophthalmitis between different anti-vascular endothelial growth factor (VEGF) agents and syringe preparation technique. This multicentre study included 197,402 injections. The drugs included in this study were three Anti-VEGF agents...

Post hoc analysis of the CANTREAT randomised trial

CANTREAT, a Canadian multicentre two-year randomised trial compares treat and extend treatment (T&E) relative to the monthly administration of Ranibizumab in nAMD. Two-hundred and eighty-five treatment-naïve patients with nAMD were randomised to receive either a once-monthly dosing or T&E regimen...